FASLG and neoplasm: Hence, circumstantially, a higher FasL signaling against the tumors in TME, independent of its activity by tumor-infiltered T-cells (in response to immunotherapies), natural killer cells, stromal cells, or engineered CAR-T cells should indicate a better antitumor outcome8–10.